Metabolic reprogramming augments potency of human pSTAT3–inhibited iTregs to suppress alloreactivity

Kelly Walton,1 Mario R. Fernandez,2 Elizabeth M. Sagatys,3 Jordan Reff,4 Jongphil Kim,5 Marie Catherine Lee,4 John V. Kiluk,6 Jane Yuet Ching Hui,7 David McKenna Jr.,8 Meghan Hupp,8 Colleen Forster,1 Michael A. Linden,8 Nicholas J. Lawrence,10 Harshani R. Lawrence,10 Joseph Pidala,11 Steven Z. Pavletic,11 Bruce R. Blazar,15 Said M. Sebti,14 John L. Cleveland,2 Claudio Anasetti,11 and Brian C. Betts1

1Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA. 2Department of Tumor Biology, 3Department of Immunology, 4Department of Biostatistics and Bioinformatics, and 5Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA. 6Department of Surgery, 7Department of Laboratory Medicine and Pathology, and 8Bionet Histology Research Laboratory, University of Minnesota, Minneapolis, Minnesota, USA. 9Department of Drug Discovery and 10Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. 11Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA. 12Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. 13Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA. 14Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia USA.

Introduction

Human Tregs can suppress alloreactive T cells responsible for graft-versus-host disease (GVHD) and solid-organ allograft rejection (1–5). However, broadly suppressive calcineurin inhibitors (CNI) remain standard of care for preventing GVHD and allograft rejection, yet protection offered by CNIs is incomplete (6–8). Moreover, CNIs impair donor immunity and disrupt Treg function and survival, thus opposing durable immune tolerance (9, 10). Further, CNIs also increase the risk for opportunistic infections and secondary malignancies among transplant recipients (11).

In contrast, adoptive transfer of human Tregs has been shown safe, and emerging data have shown efficacy in preventing GVHD after allogeneic hematopoietic cell transplantation (alloHCT) (5, 12). Modification of standard GVHD prophylaxis regimens, such as incorporating mTOR inhibitors and/or low-dose IL-2, improves Treg reconstitution after alloHCT (9, 10, 13–16) and supports Treg persistence after adoptive transfer (12). Accordingly, contemporary phase 1/II clinical trials are underway investigating the benefit of human Tregs in the prevention of GVHD and solid-organ transplant rejection (2, 15, 17, 18).
Clinical scale production of human Tregs is complex, requires local cell therapy expertise, and current good manufacturing practices–compliant (cGMP-compliant) protocols for Treg purification and expansion. The use of peripheral or “natural” Tregs versus induced Tregs is a key translational consideration. Peripheral Tregs are rare in circulation but offer reliable suppressive potency and phenotypic stability compared with induced Tregs (iTregs) (12, 19). However, circulating peripheral Tregs are scarce and raise the risk of production failure when using typical starting material for product manufacturing, like apheresis mononuclear cells. Conversely, iTregs are generated from a large and readily available pool of conventional T cells (Tconv), yet these have a theoretical risk of reverting to inflammatory Tconv (20). On the other hand, the large numbers of Tconv that can seed iTreg production mitigates hurdles regarding production. Thus, strategies to improve the phenotypic stability and potency of human iTregs are clearly warranted.

We have previously shown that STAT3 phosphorylation (pSTAT3) inhibition enhances the generation and phenotypic stability of human iTregs by provoking the demethylation of the Treg-specific demethylated region (TSDR) present in FOXP3, leading to increases in FOXP3 expression (21). As such, targeting pSTAT3 reduces the risk for Tconv reversion by the generated iTregs (21). Here we provide preclinical proof-of-concept evidence that adoptive transfer of human pSTAT3–inhibited iTregs have superior potency compared with control iTregs in suppressing alloreactive donor T cells, and in improving skin graft survival by limiting pathogenic T cell tissue invasion. Importantly, pSTAT3-inhibited iTregs reduce xenogeneic GVHD and preserve donor antileukemia immunity, a fundamental benefit of alloHCT.

Our human skin graft/NSG mouse xenotransplantation model is well suited to study human iTregs as the cells readily engraft in the immunodeficient mouse and skin is a clinically relevant organ in GVHD (22, 23). Skin is also a critical driver of alloreactivity and a well-established tissue to test experimental tolerance induction (24–26). Further, the model lends itself to the study of allospecific Tregs, as the Tregs are expanded with DCs from the skin donor.

Although targeting pSTAT3 significantly improves human iTreg potency, we demonstrate that pSTAT3 inhibition provokes a metabolic shift in iTregs from oxidative phosphorylation (OxPhos) toward glycolysis. We show cotreatment with coenzyme Q10 (CoQ10) restores OxPhos in pSTAT3-inhibited iTregs and further enhances their suppressive potency against alloreactive T cells. These findings support testing the safety and efficacy of metabolically tuned, human pSTAT3–inhibited iTregs in transplantation tolerance.

Results

Human pSTAT3–inhibited iTregs demonstrate superior suppressive potency. Human iTregs were generated as described previously, using Treg-depleted CD4+ T cells stimulated by allogeneic DCs for 5 days (T/DC ratio 30:1) (21). The pSTAT3 inhibitor (27) S3i-201 (50 μM) or DMSO (<0.01%) was added once on day 0. The concentration of S3i-201 was previously optimized to potently suppress pSTAT3 while permitting pSTAT5 activity beneficial for Treg differentiation (21). Human recombinant IL-2 (10 IU/ml) was supplemented every other day. On day +5 of culture, the T cells were harvested and iTregs were purified by CD25+ magnetic bead isolation. The final purity of the iTreg (CD4+, CD127−, CD25+, Foxp3+) (28, 29) product was >90% (Figure 1A). iTreg function was tested in standard suppression assays against DC-allostimulated T cells (22, 23, 30). Neither S3I-201 nor DMSO was added to the 5-day suppression assay cultures. The pSTAT3-inhibited iTregs demonstrated significant suppressive potency against DC-allostimulated T cells compared with DMSO-treated iTregs (Figure 1B). This enhanced iTreg suppression was achieved when either DC or bead stimulators were used during iTreg generation (Figure 1C), supporting the notion that the STAT3 inhibitor acts primarily on iTregs and not DCs. Silencing of human STAT3 during iTreg differentiation using a validated siRNA confirmed that inhibiting STAT3 augments their suppressive activity against alloreactive T cells in vitro (Figure 1D).

Mechanistically, the superior suppressive activity of pSTAT3-inhibited iTregs was associated with an increased frequency of GARP+ and PD-1+ iTregs (Figure 1, E–H). In contrast, the expression of other immunosuppressive molecules on iTregs, such as CD39, LAG3, and CTLA4 (Figure 1, I–K), was not affected by pSTAT3 inhibition. Upregulation of PD-1 and GARP in pSTAT3-inhibited iTregs was functionally relevant because neutralization of PD-1 or LAP/TGF-β1, the ligand for GARP (31, 32), with monoclonal antibodies significantly impaired the suppressive function of the pSTAT3-inhibited iTregs (Figure 1L). Conversely, inhibiting the CD39 ectonucleotidase with ARL67156 (30) had no effect on pSTAT3-inhibited iTreg potency (Figure 1L).
Human pSTAT3–inhibited iTregs significantly reduce skin graft rejection. Skin is an important and clinically relevant GVHD-target organ (33, 34). To test the activity of pSTAT3-inhibited iTregs in vivo, we used our established human skin graft/NSG mouse xenogeneic model (22, 23). NSG mice received a 1-cm² split thickness human skin graft. The mice rested for 30 days to permit skin graft healing and engraftment. During this time, human monocyte–derived DCs were generated from blood of the skin graft donor. These DCs were used to expand antigen-specific pSTAT3-inhibited iTregs or DMSO-treated controls from a healthy donor. The skin-grafted mice were then transplanted with 5 × 10⁶ human PBMCs to induce graft rejection, along with either 1 × 10⁵ pSTAT3-inhibited iTregs or DMSO-treated iTregs, or no iTregs. Thus, the iTregs were autologous to the PBMCs and allogeneic to the skin. The skin grafts were monitored daily for signs of rejection, including ulceration, necrosis, and scabbing (22, 23). Skin grafts that were >75% nonviable were considered rejected. Notably, human skin grafts from mice inoculated with pSTAT3-inhibited iTregs had significantly improved graft survival versus experimental groups treated with vehicle-treated iTregs or PBMCs alone (Figure 2, A and B), and H&E sections from skin grafts on day +21 showed a trend toward reduced rejection pathology within the tissue at this early time point (Figure 2, C and D). Ki-67 staining revealed normal proliferation of basal keratinocytes but highly proliferative, tissue-invasive donor lymphocytes (35) in the dermis of skin grafts from mice receiving control PBMCs or untreated iTregs. In contrast, there were significantly reduced numbers of dermal Ki-67⁺ cells in the skin grafts from the pSTAT3-inhibited iTreg cohort (Figure 2, E and F). Human pSTAT3–inhibited iTregs also significantly reduced xenogeneic GVHD of the lung, an important target organ in this model (30),
whereas DMSO-treated iTregs were similar to PBMCs alone (Figure 2, G and H). Importantly, human pSTAT3–inhibited iTregs engrafted, expanded in vivo, and clones were detectable by TCR-Vβ sequencing on day +21 (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.136437DS1).

Human pSTAT3–inhibited iTregs produce ample IL-9 and support cutaneous mast cells. Cutaneous lymphocyte-associated antigen (CLA) is critical for T cells to traffic to the skin, especially in the setting of inflammatory conditions (36). Additionally, IL-9 is an immunosuppressive cytokine produced by Tregs and implicated in tissue tolerance. In particular, IL-9 supports mast cells that provide localized immune suppression and can prevent graft rejection in transplanted rodents (37). Compared with DMSO-treated iTregs, pSTAT3 inhibition significantly increased the frequency of IL-9+, CLA+ iTregs (Figure 3, A and B). Moreover, NSG mice inoculated with pSTAT3-inhibited iTregs exhibited significantly greater numbers of human mast cells in their skin xenografts (Figure 3, C and D).

Human pSTAT3–inhibited iTregs significantly reduce skin graft infiltration by pathogenic Th2 cells. To assess effects of pSTAT3-inhibited human iTregs on T cells within the graft, NSG mice were transplanted with human skin (22, 23) and then inoculated with allogeneic human PBMCs alone or in combination with pSTAT3-inhibited or vehicle-treated iTregs. On day +21, the mice were humanely euthanized, and the skin grafts were harvested, preserved, and later analyzed by IHC to determine the content of T cell subsets. Human CD4+ T cells were significantly reduced in the grafts from mice treated with pSTAT3-inhibited iTregs, compared with
PBMCs alone or PBMCs plus DMSO-treated iTregs (Figure 4A). The numbers of Tregs (CD4+, Foxp3+) and Th1 cells (CD4+, T-Bet+) within the skin grafts were similar among mice inoculated with PBMCs alone or in combination with either Treg treatment (Figure 4, B, C, and E). In contrast, numbers of Th2 (CD4+, GATA3+) cells, which are implicated in T cell-mediated inflammatory skin syndromes (38), were significantly reduced in the skin grafts of transplanted mice treated with pSTAT3-inhibited iTregs cells, compared with mice inoculated with PBMCs alone or in combination with vehicle-treated iTregs (Figure 4, D and E).

Human pSTAT3–inhibited iTregs significantly reduce pathogenic Th1 cells in the spleen. To determine the effects of pSTAT3-inhibited iTregs on peripheral T cells beyond the skin grafts, transplanted mice were humanely euthanized on day +21 and human T cells were isolated from the mouse spleens for phenotyping by flow cytometry. The spleens of mice treated with pSTAT3-inhibited iTregs were markedly smaller than mice inoculated with PBMCs alone or with DMSO-treated iTregs (Supplemental Figure 1). Further, total numbers of human CD4+ and CD8+ T cells in the spleen were significantly decreased in mice treated with pSTAT3-inhibited iTregs (Figure 5, A and B). This included proportional reductions in human central memory (CD62L+CD45RO−), effector memory (CD62L−CD45RO+), and naive (CD62L−CD45RO−) T cells residing in the spleen (Figure 5, A and B) (39). Th1 cells (CD4+, IFN-γ+) are implicated in GVHD and allograft rejection (40, 41). Although Th1 cells were unchanged in the skin grafts, the amount of pathogenic Th1 cells was significantly decreased in the spleens of mice treated with pSTAT3-inhibited iTregs, compared with PBMCs alone (Figure 5, C–E). Mice that received DMSO-treated iTregs demonstrated a modest, not statistically significant reduction in Th1 cells, compared with PBMCs alone (Figure 5, C–E).

Unlike the skin grafts, the amount of human Th2 cells (CD4+, IL-4+) in the spleen was similar among all experimental groups (Figure 5, E–G). To gain insights into how pSTAT3-inhibited iTregs influence skin-homing of Th2 cells, we cocultured iTregs with DC-allostimulated T cells. Interestingly, Th2 cells cultured with pSTAT3-inhibited iTregs expressed significantly less CLA (Figure 5, H and I), which is critical for T cell homing to inflamed skin (36). Thus, pSTAT3-inhibited iTregs limit Th2 homing and infiltration of allogeneic skin tissue but permit their differentiation peripherally.

Human pSTAT3–inhibited iTregs reduce the amount of alloreactive Tconv and pathogenic Th17 cells in the periphery. Next, we investigated whether adoptive transfer of pSTAT3-inhibited iTregs affected the amount of Treg or Tconv in the recipient spleens with further flow cytometry analyses. The frequency and absolute number of human splenic Tregs was similar across the experimental groups (Figure 6, A–D).

Figure 3. Human pSTAT3–inhibited iTregs produce ample IL-9 and support cutaneous mast cells. pSTAT3-inhibited or DMSO-treated human iTregs were generated as described. (A) Contour plots and (B) graph (max, min, median) shows the frequency of IL9+, CLA+ CD4+ iTregs after expansion with S3i-201, or DMSO for 5 days from 3 independent experiments. NSG mice received a human skin graft, allogeneic PBMCs, and pSTAT3–inhibited (S3i) or control iTregs. On day +21, the skin grafts were analyzed for mast cell content by tryptase expression using IHC. (C and D) Graph (max, min, median) and representative images show skin grafts from mice treated with pSTAT3–inhibited iTregs demonstrated significantly more mast cells (tryptase = red). n = 3 independent experiments with 9 mice/group. Paired t test (B and C). *P < 0.05 or **P = 0.001–0.01. pSTAT3, STAT3 phosphorylation; iTregs, induced Tregs.
Although the frequency of human, activated (CD4+, CD127+, CD25+) Tconv in the spleen was similar among the experimental groups, mice treated with pSTAT3-inhibited iTregs demonstrated a significant reduction in the absolute number of activated Tconv (Figure 6, B, E, and F). There was also a trend for increases in the ratio of Treg/activated Tconv among mice treated with pSTAT3-inhibited iTregs (Figure 6G).

Th17 cells can develop from ex-Treg, that is, CD4+ T cells that lose Foxp3 expression in vivo (42). Moreover, Th17 cells are sufficient to induce GVHD or allograft rejection (40, 43). Importantly, the frequency of human Th17 cells in the spleen was also significantly reduced in mice treated with pSTAT3-inhibited iTregs, versus mice inoculated with PBMCs alone or vehicle-treated iTregs (Figure 7).

Human pSTAT3–inhibited iTregs maintain antileukemia immunity by donor T cells. Using our established method to generate human antitumor cytotoxic T lymphocytes (CTLs) in vivo (22, 23), we tested the effects of pSTAT3-inhibited iTregs on the antileukemia immunity of donor T cells. CTLs were generated in human PBMC–xenotransplanted NSG mice injected with pSTAT3-inhibited iTregs or DMSO-treated iTregs, where an inoculum of irradiated U937 cells was administered on day 0 and day +7. Unvaccinated, xenotransplanted mice served as a negative control. As the iTregs were expanded with skin-donor DCs, the pSTAT3-inhibited iTregs were designed to be antigen-specific and did not inhibit CTL generation or their lytic function against leukemia. Further, CTLs from mice injected with pSTAT3-inhibited or vehicle-treated iTregs were similar in their enhanced killing capacity against U937 targets in vitro, compared with unvaccinated controls (Figure 8). Thus, although antigen-specific, pSTAT3-inhibited iTregs significantly suppress alloreactive T cells and skin graft rejection, they spare donor antileukemia immunity.

Metabolic reprogramming increases the potency of pSTAT3-inhibited iTregs. STAT3 mediates proinflammatory IL-6 receptor signaling and is necessary for optimal electron transport chain (ETC) activity in the mitochondria (44, 45). Foxp3 directs oxidative phosphorylation (OxPhos) in iTregs (46), whereas Tconv prefer glycolysis (44, 47, 48). Others have demonstrated that Tregs that utilize glycolysis and exhibit reduced OxPhos are dysfunctional (49). Notably, pSTAT3 inhibition in iTregs compromised OxPhos (Figure 9A).
RESEARCH ARTICLE

and induced a shift toward glycolysis (Figure 9B). To test if this detrimental effect on OxPhos by pSTAT3 inhibition could be overcome, we generated iTregs with S3i-201 and CoQ10, as CoQ10 can replace electron deficiencies by directly stimulating complex II of the ETC (50). These studies revealed that CoQ10 treatment elevated basal and restores the maximal spare capacity for OxPhos in pSTAT3-inhibited iTregs (Figure 9A), and significantly decreased glycolysis (Figure 9B). Notably, CoQ10 treatment further augmented the suppressive potency of pSTAT3-inhibited iTregs in vitro (Figure 9C). Finally, in the human skin/NSG mouse xenograft model, pSTAT3-inhibited iTregs treated with CoQ10 augmented protection from alloreactive T cells in vivo, whereas human iTregs generated with S3i-201 and CoQ10 were superior at reducing skin graft rejection compared with pSTAT3 inhibition alone (Figure 9, D and E). Indeed, rescuing OxPhos in pSTAT3-inhibited iTregs by ex vivo treatment with CoQ10 optimized their suppressive potency, where 90% of the transplanted mice were free of graft rejection (Figure 9D).

Discussion

Here we demonstrate that adoptive transfer of human pSTAT3–inhibited iTregs prevents skin graft rejection and xenogeneic GVHD by donor T cells. Therefore, adoptive transfer of pSTAT3-inhibited iTregs could benefit recipients of solid-organ allografts or alloHCT alike, to prevent graft rejection or GVHD, respectively. Mechanistically, pSTAT3 inhibition in iTregs augments demethylation of the FOXP3 TSDR and Foxp3 expression, stabilizing their suppressive phenotypic (21), and here we show this is associated with increased expression of the immune checkpoints GARP and PD-1 that are important for the enhanced potency of the pSTAT3-inhibited iTregs. Importantly, our current study offers preclinical proof-of-concept evidence...
that pSTAT3-inhibited iTregs (a) have superior suppression over alloreactive human T cells in vivo; (b) limit tissue invasion by pathogenic Th2 cells into skin, a highly antigenic tissue and common GVHD target organ; (c) recruit immunosuppressive mast cells via IL-9; (d) significantly reduce alloreactive Tconv, Th1, and Th17 cells in the periphery; and (e) preserve donor antileukemia activity, a key benefit of alloHCT. Moreover, the infused human pSTAT3–inhibited iTregs persist and expand in vivo.

Increased IL-6 responsiveness and STAT3 phosphorylation in CD4+ T cells is associated with high rates of grade II–IV acute GVHD (16, 51). STAT3 competes with STAT5 for access to \( \text{FOXP3} \) promoters and antagonizes Treg development (52, 53). We previously attempted to enhance Treg expansion and peripheral induction early after alloHCT by polarizing pSTAT5 signaling in circulating CD4+ T cells in our phase II GVHD prevention trial of low-dose IL-2 (16). In that study, we achieved a significant, but temporary, increase in Treg reconstitution (16). Specifically, although IL-2 improved pSTAT5 activity in donor CD4+ T cells, this regimen failed to mitigate aberrant pSTAT3 activation in the same cells, and most patients that developed grade II-IV acute GVHD exhibited high numbers of circulating pSTAT3+CD4+ T cells (16). Systemic pSTAT3 inhibition is, however, translationally challenging because current small molecule inhibitors are limited by toxicity (54). Thus, we hypothesized that directly inhibiting STAT3 phosphorylation during the generation of iTreg ex vivo, followed by their adoptive transfer to transplant recipients, could significantly suppress alloreactive T cells and reduce GVHD.

Although several GVHD prevention trials using peripheral or “natural” Tregs have been conducted (2, 12, 18), very few have tested iTregs for the same indication (55). In solid-organ transplantation, early phase trials are currently underway to investigate the safety and preliminary efficacy of human peripheral, but not induced, Tregs in allograft rejection prophylaxis (17). From a translational perspective, iTregs offer an advantage over peripheral Tregs because they come from a large and readily available pool of CD4+ Tconv, compared with an otherwise rare population of peripheral Tregs. Thus, iTregs are amenable to efficient clinical scale production. However, iTregs suffer from phenotypic instability.
and can revert to potentially inflammatory Tconv (56). Likely given this plasticity, adoptive transfer of iTregs for GVHD prevention in preclinical models has shown mixed efficacy, where human iTregs showed efficacy in reducing xenogeneic GVHD (57), but murine iTregs failed to prevent GVHD (56). Further, in a phase I trial, human iTregs have safely been administered as GVHD prophylaxis, yet the trial was not powered to test efficacy and did not appear to significantly reduce GVHD (55). Similarly, in our preclinical xenogeneic NSG model, vehicle-treated iTregs failed to protect recipients against human skin graft rejection, yet, importantly, they did not accelerate rejection or xenogeneic GVHD. In contrast and importantly, we have shown that inhibiting pSTAT3 optimizes iTreg suppressive functions to overcome tissue rejection by alloreactive human T cells.

Though pSTAT3 inhibition enhances iTreg potency and stabilizes its suppressive phenotype, mitochondrial STAT3 is necessary for optimal activity of the ETC (44, 45). In accord with these studies, here we show that pSTAT3 inhibition compromises OxPhos in iTregs and provokes a shift toward glycolysis. Given these findings, we reasoned that although pSTAT3-inhibited iTregs significantly reduce alloreactive T cells, impaired OxPhos might limit iTreg fitness and long-term durability. Indeed, we showed that treatment with CoQ10, which is accepted by complex II of the ETC and facilitates OxPhos by shuttling electrons to complex III in the mitochondria (50), rescues OxPhos in pSTAT3-inhibited iTregs, and further augments their suppressive potential against alloreactive T cells both in vitro and in vivo. In contrast, adding CoQ10 to vehicle-treated iTregs further improved OxPhos but did not affect their suppressive function. We conclude that increased OxPhos alone is insufficient to enhance iTreg potency and that other targets affected by pSTAT3 inhibition also contribute to the superior suppressive responses of these iTregs (e.g., PD-1 and GARP). Our findings are consistent with those of the Chi Lab and others (49), in
which Tregs that use glycolysis over OxPhos exhibit limited suppressive function. However, it is important to note that glycolysis is possibly beneficial in other aspects of Treg biology, such as migration (58) and differentiation (59). Although we investigated the effects of pSTAT3 inhibition on iTreg metabolism, it is also possible that S3I-201 and/or CoQ10 may have important biologic effects beyond those identified in the present study.

Adoptive transfer of metabolically tuned, pSTAT3-inhibited iTregs is a readily translatable strategy to prevent GVHD or graft rejection mediated by alloreactive human T cells. Moreover, pSTAT3-inhibited iTregs preserve donor antileukemia activity necessary for the beneficial graft-versus-leukemia effect. Despite recent FDA approvals for agents to treat steroid refractory acute (60) and chronic GVHD (61), advances in GVHD prevention are needed. Additionally, innovative approaches are needed in solid-organ allotransplantation to reduce dependence on broadly suppressive calcineurin inhibitors and glucocorticoids. Thus, we are actively scaling up production of these iTregs to clinically test in GVHD prophylaxis. We predict that pSTAT3 inhibition combined with effective metabolic reprogramming by CoQ10 will provide highly effective CD4+ iTreg-based GVHD prophylaxis and submit that this strategy warrants full clinical investigation.

**Methods**

**Monoclonal antibodies and flow cytometry.** Fluorochrome-conjugated mouse anti–human monoclonal antibodies included anti-CD3, CD4, CD25, CD45RO, CD62L, CD127, GARP, PD-1, CD39, LAG3, CTLA4, IL-9, CLA, Foxp3, Ki-67, IFN-γ, IL-17A, and IL-4 (BD Biosciences; Cell Signaling Technology) (Supplemental Table 2). LIVE/DEAD Fixable Yellow or Aqua Dead Cell Stain (Life Technologies) was used to determine viability. Live events were acquired on a BD FACSCanto II or LSRII flow cytometer (FlowJo software, ver. 7.6.4; TreeStar).

**Treg generation and functional experiments.** Tregs were defined as CD4+, CD127+, CD25+, and Foxp3+ cells (28, 29). Induced Tregs were generated by stimulating purified CD4+, CD25 T cells with allogeneic monocyte-derived DCs (T cell to DC ratio = 30:1) for 5 days in the presence of pSTAT3 inhibitor, S3i-201
DMSO-treated iTregs (1 × 10^5) and received an inoculum of irradiated U937 cells (2 × 10^6) on day 0 and ratios for 4 hours. Tumor lysis assays were performed in vitro using a colorimetric assay (22, 23).

The skin-grafted mice were then transplanted with 5 × 10^6 human PBMCs to induce graft rejection, along with either 1 × 10^5 pSTAT3-inhibited iTregs or vehicle-treated iTregs, or no iTregs (note that the iTregs were autologous to the PBMCs, and allogeneic to the skin). The skin grafts were then monitored daily for signs of rejection, including ulceration, necrosis, and scabbing (22, 23). Skin grafts that were >75% nonviable were considered rejected.

In select experiments, mice were humanely euthanized on day +21; skin grafts and host spleens were harvested for analysis. Skin rejection was performed blinded according to standard criteria (26, 33, 38). Processed spleens cells were phenotyped by flow cytometry for Tregs, Tconv, Th1, Th2, and Th17 cells (22, 23, 30). IHC was performed on the skin grafts to identify Tregs (CD4 and Foxp3), Th1 (CD4 and T-bet), and Th2 (CD4 and GATA3) and scanned by use of ScanScope XT (Aperio Technologies) with a 200×/0.75 NA objective lens at a rate of 3 minutes per slide via Basler Tri-linear array as described (51). In addition, Ki-67 staining was conducted to identify proliferative, infiltrative lymphocytes in the dermis and tryptase staining was performed to characterize mast cell content in the grafts.

To test the effect of pSTAT3-inhibited iTreg effects on the donor T cell–mediated response against U937 leukemia cells, mice were transplanted with 5 × 10^6 human PBMCs, with or without pSTAT3-inhibited or DMSO-treated iTregs (1 × 10^6) and received an inoculum of irradiated U937 cells (2 × 10^6) on day 0 and +7 (22, 23). Control mice received PBMCs alone without tumor. Mice did not receive skin grafts for these experiments. On day +12, the mice were humanely euthanized, and the spleens were harvested. Human CD3^+ T cells within the spleens were purified by magnetic beads. Tregs were specifically not removed from the harvested T cells. The human T cells were cocultured with fresh U937 cells at varying T cell to Target ratios for 4 hours. Tumor lysis assays were performed in vitro using a colorimetric assay (22, 23).

**Metabolism experiments.** Pretreated, purified pSTAT3-inhibited or DMSO-treated iTregs (2 × 10^5) were washed once and then plated in XFe96 microplates in unbuffered DMEM containing 10 mM glucose, 1 mM sodium pyruvate, and 2 mM L-glutamine for mitochondrial stress test assays or unbuffered DMEM only for the glycolytic stress test assays. The concentration of the compounds used were as follows: 1 μM oligomycin A, 1 μM FCCP, 500 nM rotenone, 500 nM antimycin A, 10 mM glucose, and 1 mM 2-DG. Data were normalized using Calcein AM.

**Statistics.** One-way ANOVA was used for group comparisons, including a Sidak’s or Dunn’s post test for correction of multiple comparisons. A paired t test was used for paired comparisons. For comparison of survival curves, a log-rank test was used. The statistical analysis was conducted using Prism software version 5.04 (GraphPad). Statistical significance was defined by a 2-tailed P < 0.05.

**Study approval.** Skin and peripheral blood mononuclear cells were acquired from consented mastectomy patients using an IRB-approved protocol at Moffitt Cancer Center and the University of Minnesota Masonic Cancer Center. NSG mice (male or female, age 6- to 24-weeks-old) were purchased from The Jackson Laboratory and housed within American Association for Laboratory Animal Care–accredited Animal Resource Centers at Moffitt Cancer Center or the University of Minnesota. All mice were treated in adherence with the NIH Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011), and the protocols used were approved by the Moffitt Cancer Center or the University of Minnesota institutional animal care and use committees.
Author contributions
KW performed experiments, analyzed and interpreted data, and edited the manuscript. MRF performed and analyzed experiments and edited the manuscript. JR performed experiments. JK designed experiments and provided statistical expertise. MCL, JVK, and JH consented patients and acquired human skin grafts. EMS, MAL, MH, and CF performed histologic and pathologic analyses of xenograft data and edited the manuscript. NJL, HRL, and SMS synthesized S3i-201 and edited the manuscript. JP, SZP, DM Jr, ILC, BRB, and CA assisted in the design of experiments and edited the manuscript. BCB designed, led, and performed experiments, analyzed and interpreted data, and wrote the manuscript.

Acknowledgments
Our study received assistance from the Flow Cytometry Core Facility at the H. Lee Moffitt Cancer Center & Research Institute (P30-CA076292) and the Flow Cytometry Resource at the University of Minnesota, each National Cancer Institute–designated Comprehensive Cancer Centers. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1-TR002494). We acknowledge the animal care staff in the Department of Comparative Medicine at the University of South Florida and the University of Minnesota Research Animal Resources for providing technical assistance. This work was supported by the Amy Strelzer Manasevit Research Program (to BCB); NIH grant R01 HL133823 (to BCB), R01 HL11879 (to BRB), R01 HL56067 (to BRB), and R37 AI34495 (to BRB); and LLS Translational Research Grant 6462-15 (to BRB).

Address correspondence to: Brian C. Betts, Nils Hasselmo Hall, Room 2-108, 312 Church Street SE, Minneapolis, Minnesota 55455, USA. Phone: 612.625.8942; Email: Bett0121@umn.edu.
20. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol. 2007;8(3):277–284.
21. Betts BC, Veerapathran A, Pidala J, Yu ZX, Anasetti C. STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving T-cell capacity. J Leukoc Biol. 2014;95(2):205–213.
22. Betts BC, et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A. 2018;115(7):1582–1587.
23. Betts BC, et al. Inhibition of human dendritic cell ER stress response reduces T cell alloreactivity yet spares donor anti-tumor immunity. Front Immunol. 2018;9:2887.
24. Steinmuller D. Skin allograft rejection by stable hematopoietic chimeras that accept organ allografts sill is an enigma. Transplantation. 2001;72(1):8–9.
25. Boyse EA, Old LJ. Loss of skin allograft tolerance by chimeras. Transplantation. 1968;4(6):419.
26. Moseley RV, Shiel AG, Mitchell RM, Murray JE. Immunologic relationships between skin and kidney homografts in dogs on immunosuppressive therapy. Transplantation. 1966;4(6):678–687.
27. Siddiquie K, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces anti-tumor activity. Proc Natl Acad Sci U S A. 2007;104(18):7391–7396.
28. Liu W, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701–1711.
29. Seddiki N, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203(7):1693–1700.
30. Betts BC, et al. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. Sci Transl Med. 2017;9(372):eaai8269.
31. Hahn SA, et al. Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4+ T cells. Blood. 2013;122(7):1182–1191.
32. Hahn SA, et al. A key role of GARP in the immune suppressive tumor microenvironment. Sci Transl Med. 2011;3(83):83ra42.
33. Young JW, Merad M, Hart DN. Dendritic cells in transplantation and immune-based therapies. Biol Blood Marrow Transplant. 2007;13(1 suppl 1):23–32.
34. Paczesny S, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2(13):13ea2.
35. Sedor RA, Dalharu PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247–258.
36. Zelenika D, et al. Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol. 1998;161(4):1868–1874.
37. Lu LF, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006;442(7106):997–1002.
38. Laffont S, et al. CD8+ T-cell-mediated killing of donor dendritic cells prevents allograft rejection effectively. Blood. 2006;108(7):2257–2264.
39. Seder RA, Dalharu PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247–258.
40. Yu Y, et al. Prevention of GVHD while sparing GVLT effect by targeting Th1 and Th17 transcription factor T-bet and RORyt in mice. Blood. 2011;118(18):5011–5020.
41. Komatsu N, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20(1):62–68.
42. Iclozan C, et al. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(2):170–178.
43. Angelin A, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 2017;25(6):1282–1293.e7.
44. Wegzyn J, et al. Function of mitochondrial Stat3 in cellular respiration. Science. 2009;323(5915):793–797.
45. Howie D, et al. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight. 2017;2(3):e89160.
46. Pacella I, et al. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. Nat Immunol. 2016;17(3):277–285.
47. Wei J, et al. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. Nat Immunol. 2016;17(3):277–285.
48. Echtay KS, Winkler E, Klingenberg M. Coenzyme Q is an obligatory cofactor for uncoupling protein function. J Exp Med. 2007;204(18):7391–7396.
49. Yao Z, et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. J Exp Med. 2007;204(18):7391–7396.
50. Laurence A, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. J Exp Med. 2007;204(18):7391–7396.
51. Laurence A, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. J Exp Med. 2007;204(18):7391–7396.
52. Laurence A, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. J Exp Med. 2007;204(18):7391–7396.
53. Laurence A, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. J Exp Med. 2007;204(18):7391–7396.
58. Kishore M, et al. Regulatory T cell migration is dependent on glucokinase-mediated glycolysis. *Immunity*. 2017;47(5):875–889.e10.
59. De Rosa V, et al. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. *Nat Immunol*. 2015;16(11):1174–1184.
60. Przepiorka D, et al. FDA Approval Summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. *Oncologist*. 2020;25(2):e328–e334.
61. Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. *Blood Adv*. 2018;2(15):2012–2019.
62. Betts BC, St Angelo ET, Kennedy M, Young JW. Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses. *Blood*. 2011;118(19):5340–5343.